| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V51139 | Blontuvetmab (AT-004; VT-007) | 1608112-78-2 | Blontuvetmab (AT 004) is a canine CD20 monoclonal antibody (mAb). |
|
V51118 | Denintuzumab (hBU-12) | 1630074-14-4 | Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody (mAb). |
|
V51134 | Divozilimab (BCD-132) | 2254061-60-2 | Divozilimab (BCD-132) is a humanized monoclonal antibody (mAb) against CD20 (CD20). |
|
V79330 | Eramkafusp Alfa | Eramkafusp Alfa is a human IgG1 antibody targeting the mouse B lymphocyte CD20 antigen MS4A1. | |
|
V51138 | Imvotamab (IGM-2323) | 2573121-53-4 | anti-CD20/3 bispecific antibody (bsAb) |
|
V51136 | Ocaratuzumab (AME-133v) | 1169956-08-4 | Ocaratuzumab (AME 133v), an Fc-engineered antibody, is a humanized IgG1 anti-CD20 monoclonal antibody (mAb) with a Kd of ~100 pM. |
|
V74761 | Ocrelizumab (Omelizumab; Ocrevus) | 637334-45-3 | Omelizumab is an anti-CD20 antibody that depletes circulating immature and mature B cells but spares CD20-negative plasma cells. |
|
V51135 | Plamotamab (XmAb-13676) | 2138442-31-4 | Plamotamab (XmAb-13676) is a human bisAb (bsAb) that binds CD3 and CD20. |
|
V51132 | Ripertamab (SCT-400) | 2249927-04-4 | Ripertamab (SCT400) is a recombinant human-mouse chimeric anti-CD20 IgG1κ tumor. |
|
V51130 | Tositumomab | 192391-48-3 | Tositumomab is a mouse IgG2a lambda monoclonal antibody (mAb) targeting the CD20 antigen, which is present on the surface of normal and malignant B lymphocytes. |
|
V51133 | Ublituximab (TG-1101; LFB-R603; TGTX-1101) | 1174014-05-1 | Ublituximab (LFB-R603; TG-1101; TGTX-1101) is a next-generation type 1 chimeric monoclonal antibody (mAb) targeting a unique epitope on the CD20 antigen. |
|
V51137 | Zuberitamab (HS-006) | 2251143-19-6 | Zuberitamab (HS006) is a monoclonal antibody (mAb) targeting CD20 for use in cancer-related research like diffuse large B-cell lymphoma. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
